Pyrotinib plus antiangiogenic agents for HER2 ‐altered advanced non‐small cell lung cancer: A retrospective real‐world study

ConclusionIn this study, pyrotinib plus antiangiogenic agents demonstrated promising efficacy and were tolerable in HER2-altered NSCLC patients.

Source: Thoracic Cancer - September 23, 2023 Category: Cancer & Oncology Authors: Yaning Yang, Guangjian Yang, Weihua Li, Xuezhi Hao, Shuyang Zhang, Xin Ai, Siyu Lei, Haiyan Xu, Yan Wang Tags: ORIGINAL ARTICLE Source Type: research